Duration of Tamoxifen Use and the Risk of Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers

PURPOSE: Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80%. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. METHODS: We studied 1504 women with a known BRCA1 or BRCA2 mutat...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Gronwald, Jacek, Robidoux, Andre, Kim-Sing, Charmaine, Tung, Nadine, Lynch, Henry T., Foulkes, William D., Manoukian, Siranoush, Ainsworth, Peter, Neuhausen, Susan, Demsky, Rochelle, Eisen, Andrea, Singer, Christian F., Saal, Howard, Senter, Leigha, Eng, Charis, Weitzel, Jeffrey, Moller, Pal, Gilchrist, Dawna M., Olopade, Olufunmilayo, Ginsburg, Ophira, Sun, Ping, Huzarski, Tomasz, Lubinski, Jan, Narod, Steven A.
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4131437/
https://ncbi.nlm.nih.gov/pubmed/24951267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3026-3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы